+52 weeks of upadacitinib therapy for ulcerative colitis outperformed placebo in endpoints like clinical, histological, and patient-reported outcomes.
Increasing exposure to 2.5 µm particulate matter increases the risk of non-small cell lung cancer in non-smoking individuals with EGFR mutations.
Final study analysis did not show benefit in advanced hepatocellular carcinoma, but lenvatinib's role as standard first-line treatment in aHCC was supported.
Primary sclerosing cholangitis patients who received colectomy with ileostomy had a higher survival chance without liver transplant than those without surgery.
I.V. N-acetylcysteine demonstrated mucolytic and expectorant efficacy in hospitalised patients with respiratory diseases and abnormal mucus secretion.
LVRS was not highly superior to bronchoscopic lung volume reduction with valve placement for emphysema patients eligible for both treatment options.
Therapy with mirikizumab leads to a higher percentage of patients achieving resolution of active colonic inflammation with absence of neutrophils at induction.
Burden was greatly reduced with a digital tool set that informed evidence-based care with data on medication adherence, inhaler technique, and peak flow.
Durable benefits for endobronchial one-way SVS valves over only medical management for hyperinflation in severe heterogenous emphysema.
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease failed its primary endpoint, but may benefit RAILD patients with usual interstitial pneumonia.
Cirrhotic patients had insufficient T cell reactivity after 2 mRNA vaccine doses. But a booster and a natural infection led to higher antibody levels in this group.
Early intervention with favipiravir did not improve clinical outcomes for hospitalised patients, but the agent may induce health benefits for patients under 60 years of age.
Deep learning from digitalised haematoxylin and eosin-stained whole-tumour slide images outperformed classical Miettinen relapse risks prediction.
Brensocatib did not improve the health status of patients with severe COVID-19. Active neutrophil elastase was decreased in treated patients without benefit.
Compared with usual care, a web-based, self-management support tool improved physical activity levels of COPD patients, suggest preliminary trial results.
Long-acting bronchodilators do not appear to improve respiratory symptoms in symptomatic tobacco-exposed individuals, Rethinc trial data suggests.
Corticosteroids improved lung function for premature children. A study suggests that bronchodilator responsiveness helps screening patients for this approach.
With an acceptable safety profile and promising efficacy data, nintedanib is a potential candidate for pediatric fibrosing interstitial lung disease treatment.
Treatment with nivolumab/ipilimumab for 4 weeks achieved a major pathological response in 95% of patients with stage III dMMR colon cancer.
Azithromycin should be avoided in early-life, severe rRSV bronchiolitis due to association with higher recurrent wheezing risks. Other antibiotics may have the same harmful effect.